NCT03524430 (BREVITY) is a NA clinical trial of Core needle biopsy in Breast Neoplasm Female, sponsored by Rna Diagnostics Inc..

Who is sponsoring NCT03524430?

NCT03524430 is sponsored by Rna Diagnostics Inc..

What drugs are being tested in NCT03524430?

Interventions in NCT03524430: Core needle biopsy.

What condition does NCT03524430 study?

NCT03524430 studies Breast Neoplasm Female.

Is NCT03524430 still recruiting?

NCT03524430 is currently recruiting now. Last updated 14 October 2025.

Last reviewed 2025-10-14 · How we verify

NCT03524430: BREVITY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

Recruiting now NA Last updated 14 October 2025

What this trial tests

NA trial testing Core needle biopsy in Breast Neoplasm Female in 801 participants. Currently enrolling.

Timeline

26 April 2018

Primary endpoint
30 July 2026

31 March 2031

Quick facts

Lead sponsor	Rna Diagnostics Inc.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	801
Start date	26 April 2018
Primary completion	30 July 2026
Estimated completion	31 March 2031
Sites	7 locations across France, Italy, Germany, Poland, Canada, United States, Spain

Drugs / interventions tested

Core needle biopsy

Conditions studied

Breast Neoplasm Female — all drugs for Breast Neoplasm Female →

Sponsor

Rna Diagnostics Inc.

Who can join

18 and older, female only, with Breast Neoplasm Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

RNA modifications in cancer.
Wu H, Chen S, Li X, Li Y, et al · · 2025 · cited 5× · PMID 39802639 · DOI 10.1002/mco2.70042
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.
Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, et al · · 2025 · cited 2× · PMID 40790765 · DOI 10.1186/s13058-025-02092-9
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.
Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, et al · · 2024 · cited 2× · PMID 38113421 · DOI 10.1093/jncics/pkad107
Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility.
Parissenti AM, Noubir S, Pritzker LB, Kovala T, et al · · 2025 · PMID 40940865 · DOI 10.3390/cancers17172769

Verify or expand the search:

Other trials of Core needle biopsy

Trials testing the same drug.

NCT07121998 — Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms · recruiting
NCT05435352 — Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment · terminated
NCT04067726 — RANKL Inhibition and Mammographic Breast Density · Phase 2 · active not recruiting
NCT03741517 — Biomarker Study of Pancreatic Neuroendocrine Tumours · unknown

Other recruiting trials for Breast Neoplasm Female

Currently open trials in the same condition.

NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
NCT06711523 — Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy · Phase 3 · active not recruiting
NCT05277935 — Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib · NA · recruiting
NCT06234137 — A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrot · NA · recruiting
NCT04812652 — Digitally Distributed Yoga for Women Treated for Breast Cancer · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03524430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rna Diagnostics Inc.
Last refreshed: 14 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03524430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing